SINGAPORE, 25 August 2026 – ChemT Biotechnology has been named to the Forbes Asia 100 to Watch 2026 list in the Biotechnology & Healthcare category.

Now in its sixth edition, the Forbes Asia 100 to Watch list spotlights 100 emerging companies and startups across the Asia-Pacific region that are driving innovation across sectors including biotechnology, healthcare, robotics, finance and retail.

We’re honored to be recognized for our work in applying AI to make biologics development and manufacturing more predictable, efficient, and scalable. Through our AI-powered Virtual Cell platform, CelMo™, we aim to better understand and control cell behavior, accelerate bioprocess development, and ultimately transform how therapies are developed, manufactured, and delivered to patients.

The recognition comes as ChemT continues to expand the development and application of CelMo™ across different cellular systems and biomanufacturing workflows. Being named to the Forbes Asia 100 to Watch reflects ChemT’s continued progress towards its mission to transform how therapies are developed, manufactured and delivered to patients around the world.

Learn more here:https://www.forbes.com/sites/ranawehbe/2026/08/24/forbes-asia-100-to-watch-2026/

For more information, please contact corporate@chemtbio.com.